Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 4 art units • 5 examiners • 0 of 6 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Novaliq GmbH currently manages 6 pending office actions within the Biotechnology & Pharmaceuticals technology area. This portfolio is distributed across 4 distinct art units, suggesting a focused but multi-disciplinary approach to their pharmaceutical innovations. The involvement of 5 distinct examiners indicates that most pending matters are being handled by different individuals, which may lead to varied prosecution experiences across the portfolio.
PALENIK, JEFFREY T is identified as the busiest examiner for this company, currently overseeing 2 pending office actions. This concentration means that 2 of the 6 total pending actions are centralized with a single official. For practitioners, this highlights the importance of understanding this specific examiner's patterns, as their decisions impact a portion of the current Biotechnology & Pharmaceuticals filings.
The spread of these actions across 5 examiners and 4 art units shows a high degree of examiner diversity relative to the total volume of pending work. With the busiest examiner handling a portion of the cases, the remaining actions are spread among other examiners. This distribution suggests that while PALENIK, JEFFREY T is a primary point of contact, the overall prosecution strategy must remain adaptable to the requirements of several different art units and examiners simultaneously.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (17%) |
| Double-patenting + other | 3 (50%) |
| Multi-statute (no §101) | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PALENIK, JEFFREY T | 2 | 53.6% | +27.2% |
| YU, HONG | 1 | 30.9% | +5.6% |
| PECKHAM, RICHARD GRANT | 1 | 68.1% | +35.1% |
| HOERNER, PAUL ELLSWORTH | 1 | 50.0% | +62.1% |
| MOU, LIYUAN | 1 | 42.9% | +59.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18784569 | OPHTHALMIC COMPOSITION FOR TREATMENT OF DRY EYE DISEASE | PALENIK, JEFFREY T | — |
| 17751512 | SUSPENSION COMPRISING A PROTEIN PARTICLE SUSPENDED IN A NON-AQUEOUS VEHICLE | HOERNER, PAUL ELLSWORTH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17350427 | SEMIFLUORINATED COMPOUNDS | MOU, LIYUAN | 25d overdue |
| 19540268 | OPHTHALMIC COMPOSITION FOR TREATMENT OF DRY EYE DISEASE | PALENIK, JEFFREY T | — |
| 18897877 | SEMIFLUORINATED COMPOUNDS AND THEIR COMPOSITIONS | PECKHAM, RICHARD GRANT | — |
| 18784569 | OPHTHALMIC COMPOSITION FOR TREATMENT OF DRY EYE DISEASE | PALENIK, JEFFREY T | — |
| 17751512 | SUSPENSION COMPRISING A PROTEIN PARTICLE SUSPENDED IN A NON-AQUEOUS VEHICLE | HOERNER, PAUL ELLSWORTH | — |
| Art Unit | Apps |
|---|---|
| 1615 | 2 |
| 1614 | 1 |
| 1611 | 1 |
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19540268 | OPHTHALMIC COMPOSITION FOR TREATMENT OF DRY EYE DISEASE | PALENIK, JEFFREY T | 1615 | §102Other | Final Rejection | — | Pending | Feb 13, 2026 |
| 19274087 | O/W-EMULSIONS COMPRISING SEMIFLUORINATED ALKANES | YU, HONG | 1614 | §103§112DP | Non-Final OA | — | Pending | Jul 18, 2025 |
| 18897877 | SEMIFLUORINATED COMPOUNDS AND THEIR COMPOSITIONS | PECKHAM, RICHARD GRANT | — | §112DP | Non-Final OA | — | Pending | Sep 26, 2024 |
| 18784569 | OPHTHALMIC COMPOSITION FOR TREATMENT OF DRY EYE DISEASE | PALENIK, JEFFREY T | 1615 | §103§112Other | Non-Final OA | — | Pending | Jul 25, 2024 |
| 17751512 | SUSPENSION COMPRISING A PROTEIN PARTICLE SUSPENDED IN A NON-AQUEOUS VEHICLE | HOERNER, PAUL ELLSWORTH | 1611 | §103§112 | Non-Final OA | — | Pending | May 23, 2022 |
| 17350427 | SEMIFLUORINATED COMPOUNDS | MOU, LIYUAN | 1628 | §103DP | Final Rejection | 25d overdue | Pending | Jun 17, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial